Fibrolamellar Hepatocellular Carcinoma Treatment in India

Fibrolamellar carcinoma is a rare type of primary liver cancer that most often affects adolescents and young adults. Unlike many other liver cancers, it typically develops in people who do not have long-standing liver disease. The condition arises from liver cells that undergo abnormal changes, leading to the formation of a distinct tumour within the liver.

Fibrolamellar carcinoma usually begins as a single, well-defined mass in the liver and can grow gradually over time. As the tumour enlarges, it may affect normal liver tissue and nearby structures, influencing how the liver performs its essential functions. While uncommon, fibrolamellar carcinoma has unique characteristics that are now better recognised, allowing for a clearer understanding of how the condition affects the liver.

Fibrolamellar carcinoma develops when abnormal changes occur in liver cells, leading them to grow and divide in an uncontrolled way. Unlike other liver cancers, this condition often occurs without underlying liver disease, and its exact cause is not fully understood, here are the main causes of fibrolamellar carcinoma.

Genetic Changes in Liver Cells

Fibrolamellar carcinoma is linked to specific genetic changes that affect how liver cells grow and function. These changes occur within the tumour cells themselves and are not inherited.

Abnormal Cell Signalling

Changes in cell signalling pathways can cause liver cells to multiply when they should not. Over time, this abnormal signalling contributes to tumour formation.

Disruption in Normal Liver Cell Development

In some individuals, normal liver cell development may be disrupted, leading to the formation of abnormal cells that later develop into fibrolamellar carcinoma.

Unknown Environmental or Biological Triggers

Despite ongoing research, no clear environmental exposure or lifestyle factor has been identified as a direct cause. In many cases, the exact trigger remains unknown.

Fibrolamellar carcinoma is rare and can affect people without typical liver disease, but certain factors may increase the likelihood of developing the condition. Understanding these risks helps patients and families remain informed, here are the key risk factors for fibrolamellar carcinoma.

Young Age

This cancer most often affects adolescents and young adults, unlike other types of liver cancer that usually occur later in life.

Absence of Chronic Liver Disease

Fibrolamellar carcinoma commonly develops in people with otherwise healthy livers, making it distinct from other liver cancers.

Gender

Some studies suggest a slightly higher occurrence in females, although the difference is not strongly defined.

Lack of Traditional Liver Cancer Risk Factors

People who do not have risk factors such as cirrhosis, hepatitis infection, or long-term alcohol use may still develop this condition.

Fibrolamellar carcinoma is a rare form of liver cancer that often affects adolescents and young adults without underlying liver disease. Symptoms usually develop slowly and may remain vague in the early stages, leading to delays in diagnosis. Many individuals initially attribute symptoms to digestive or lifestyle-related issues. As the tumour grows, symptoms tend to become more noticeable. Common early symptoms include:

Abdominal discomfort or vague pain

A dull ache or persistent discomfort, often in the upper right side of the abdomen, may develop as the liver enlarges.

Abdominal fullness or bloating

A feeling of pressure or fullness may occur due to the growing mass within the liver.

Loss of appetite or early satiety

Reduced appetite or difficulty eating normal portions can result from pressure on nearby organs.

Unexplained weight loss

Some individuals experience gradual weight loss without intentional dietary changes.

More advanced symptoms may include:

A palpable abdominal mass

A firm lump may be felt in the abdomen as the tumour increases in size.

Fatigue or low energy levels

Ongoing illness can lead to persistent tiredness that interferes with daily activities.

Nausea or digestive discomfort

Compression of surrounding digestive structures may affect normal digestion.

Yellowing of the skin or eyes (jaundice)

In some cases, bile flow may be affected, leading to jaundice, although this is less common in early stages.

As fibrolamellar carcinoma symptoms often resemble other benign liver or gastrointestinal conditions, thorough evaluation is important when abdominal symptoms persist or progressively worsen over time.

Diagnosing fibrolamellar carcinoma requires a careful and structured approach, as this rare form of liver cancer often occurs in young individuals without underlying liver disease. At Max Hospitals, diagnosis combines detailed clinical assessment with advanced imaging, laboratory investigations, and expert pathological evaluation to ensure accuracy and timely care.

Initial Clinical Evaluation

The diagnostic process begins with a thorough physical examination and review of symptoms and medical history. Doctors assess symptoms such as abdominal pain or swelling, unexplained weight loss, fatigue, nausea, or early fullness after meals. As fibrolamellar carcinoma typically develops in patients without cirrhosis, a detailed assessment helps distinguish it from other liver conditions. Family history and overall health status are also reviewed.

Laboratory Tests

Blood tests support the diagnostic evaluation and help assess liver function and general health:

• Liver function tests: Evaluate how well the liver is working and detect any abnormalities caused by the tumour.
• Alpha-fetoprotein (AFP) levels: Unlike other liver cancers, AFP levels are usually normal or only mildly elevated in fibrolamellar carcinoma, which can help differentiate it from hepatocellular carcinoma.
• Complete blood count (CBC): Assesses overall health and checks for anaemia or other blood abnormalities.
• Kidney function tests: Ensure kidney function is adequate before further investigations or treatment planning.

Advanced Imaging Studies

Imaging plays a central role in identifying fibrolamellar carcinoma and assessing disease extent:

• Ultrasound: Often the first imaging test, ultrasound helps detect liver masses and assess their basic characteristics.
• Computed Tomography (CT) scan: CT scans provide detailed information about tumour size, location, involvement of blood vessels, and possible spread to nearby organs or lymph nodes.
• Magnetic Resonance Imaging (MRI): MRI offers detailed images of the liver and can identify features characteristic of fibrolamellar carcinoma, such as a central scar within the tumour.
• Chest imaging: A chest X-ray or CT scan may be performed to check for spread to the lungs.

Tissue Diagnosis

While imaging findings may strongly suggest fibrolamellar carcinoma, confirmation usually requires examination of tumour tissue:

• Biopsy: In selected cases, a needle biopsy is performed to obtain a tissue sample for microscopic examination. This confirms the diagnosis and distinguishes fibrolamellar carcinoma from other liver tumours.
• Surgical specimen analysis: When surgery is undertaken, removed tissue is examined in detail to confirm the diagnosis and assess tumour characteristics.

Treatment for fibrolamellar carcinoma is planned with the primary goal of achieving durable disease control, as this cancer behaves differently from more common liver tumours. At Max Hospitals, the treatment plan is tailored to each patient after careful evaluation of tumour size, location within the liver, spread to nearby structures or distant organs, and involvement of major blood vessels. The patient’s age, general health, and liver function are also key considerations. In many cases, a stepwise approach is adopted, where surgery is prioritised, and other treatments are used to support long-term disease control or manage advanced disease.

Surgical Treatment

Surgery is the most effective treatment for fibrolamellar carcinoma and offers the best chance of long-term survival when complete tumour removal is possible.

• Partial hepatectomy: This procedure involves removal of the segment of the liver containing the tumour while preserving adequate healthy liver tissue. As fibrolamellar carcinoma usually develops in patients without cirrhosis or chronic liver disease, the remaining liver is often able to function well and regenerate after surgery. Careful pre-operative planning is essential to ensure safe removal while maintaining sufficient liver volume.
• Complete tumour resection: The aim of surgery is complete excision of the tumour with clear margins, meaning no cancer cells are left behind. Achieving clear margins significantly reduces the risk of recurrence and is a key determinant of long-term outcomes. In some cases, complex surgical techniques may be required if the tumour is located near major blood vessels.

Systemic Therapy

Systemic treatments may be considered when surgery alone is not sufficient or when the disease cannot be completely removed.

• Chemotherapy: Fibrolamellar carcinoma does not respond consistently to standard chemotherapy used for other liver cancers. However, chemotherapy may be recommended in selected situations, such as advanced disease, recurrence after surgery, or when surgery is not immediately feasible. The decision to use chemotherapy is made on an individual basis after weighing potential benefits against side effects.
• Targeted therapy and immunotherapy: Research into targeted treatments and immunotherapy for fibrolamellar carcinoma is ongoing. These therapies aim to act on specific molecular or immune pathways involved in tumour growth. In selected patients, particularly those with advanced or recurrent disease, such treatments may be considered, often as part of clinical trials or specialised treatment programmes.

Liver Transplantation

In rare and carefully selected cases, liver transplantation may be considered when the tumour cannot be removed surgically without leaving insufficient healthy liver tissue. This approach involves replacing the diseased liver with a healthy donor liver and is evaluated only after thorough assessment to ensure the best possible outcome. Transplantation may offer a potential treatment option for selected patients when conventional surgery is not feasible.

Supportive Care

Supportive care plays an important role throughout treatment, helping patients cope with symptoms, treatment-related side effects, and the emotional impact of the disease. This includes:

• Pain management and symptom control
• Nutritional support and dietary counselling to maintain strength and recovery
• Management of side effects related to surgery or systemic therapy
• Psychological and emotional support for patients and families
• Rehabilitation services to support recovery and return to daily activities

Follow-Up and Monitoring

Regular follow-up is essential after treatment to detect recurrence at an early stage and manage any long-term effects. Follow-up plans typically include clinical assessments, blood tests, and imaging studies at defined intervals. Long-term monitoring allows doctors to respond promptly to any changes and support ongoing health and quality of life.

Treatment for fibrolamellar carcinoma involves coordinated care from hepatobiliary surgeons, medical oncologists, radiologists, pathologists, transplant specialists, and supportive care teams. This multidisciplinary approach ensures that treatment decisions are well-informed, personalised, and continuously reviewed throughout the patient’s care journey.

Fibrolamellar carcinoma is a rare form of liver cancer that often affects younger individuals without underlying liver disease. If diagnosis or treatment is delayed, it may lead to several complications.

Liver Function Impairment

Tumour growth may interfere with normal liver function, affecting digestion, metabolism, and the body’s ability to process waste products.

Abdominal Pain or Swelling

Enlargement of the liver or tumour mass may cause discomfort, abdominal fullness, or visible swelling.

Spread to Nearby or Distant Organs

In advanced stages, fibrolamellar carcinoma may spread to lymph nodes or other organs, increasing disease burden and treatment complexity.

Unexplained Weight Loss and Fatigue

Ongoing cancer activity may lead to reduced appetite, weight loss, and persistent tiredness.

Bile Duct Obstruction

Involvement of bile ducts may cause jaundice, itching, or changes in urine and stool colour.

Treatment-Related Complications

Surgical procedures, chemotherapy, or targeted therapies may result in short-term side effects or long-term health considerations requiring monitoring.

Early diagnosis, timely treatment, and regular follow-up play a vital role in reducing complications and supporting long-term outcomes.

Fibrolamellar carcinoma cannot usually be prevented, as it often develops without known risk factors or underlying liver disease. However, certain measures help support early detection and timely care.

Awareness of Persistent Liver-Related Symptoms

Ongoing abdominal discomfort, unexplained weight loss, fatigue, or jaundice should be evaluated promptly.

Early Evaluation in Young Individuals

Unusual liver symptoms in adolescents or young adults should not be ignored, even in the absence of chronic liver disease.

Routine Health Assessments

Periodic medical check-ups help identify abnormal liver findings at an early stage.

Prompt Investigation of Liver Masses

Any detected liver lump or abnormal imaging finding should be assessed without delay.

Structured Follow-up After Treatment

Regular monitoring supports early detection of recurrence and management of long-term effects.

Prevention focuses on early recognition of symptoms, timely investigation of liver abnormalities, and ongoing surveillance to improve outcomes.

Is fibrolamellar carcinoma considered a fast-growing cancer?

Fibrolamellar carcinoma often grows more slowly than many other liver cancers. However, growth patterns can vary between individuals, which is why regular monitoring and timely treatment are important.

What is the long-term outlook after successful treatment?

Long-term outcomes depend on factors such as complete tumour removal, stage at diagnosis, and follow-up care. Many patients achieve prolonged disease control when treatment is undertaken early and followed by regular surveillance.

Can fibrolamellar carcinoma come back after treatment?

Yes, recurrence is possible even after successful surgery. This is why structured follow-up with imaging and clinical review is essential for early detection and management.

Does fibrolamellar carcinoma affect life expectancy?

Life expectancy varies widely and depends on tumour stage, response to treatment, and overall health. Early diagnosis and complete surgical removal are associated with better outcomes.

Is fibrolamellar carcinoma hereditary?

Fibrolamellar carcinoma is not considered an inherited cancer. The genetic changes involved occur within tumour cells and are not passed down through families.

Can patients return to normal work or studies after treatment?

Many patients are able to resume work, education, and daily activities after recovery, although timelines vary. Gradual return is advised based on physical recovery and medical guidance.

Are dietary changes required after treatment?

Most patients are advised to follow a balanced, liver-friendly diet that supports healing and overall health. Specific dietary recommendations are usually personalised based on liver function and recovery needs.

Is it safe to exercise after surgery or treatment?

Light physical activity is often encouraged during recovery, with gradual progression. Exercise plans should always be guided by the treating medical team.

Can fibrolamellar carcinoma affect fertility or pregnancy?

Fertility is usually not directly affected by the cancer itself, but certain treatments may have implications. Patients planning a family should discuss fertility preservation and pregnancy timing with their care team.

Are clinical trials available for fibrolamellar carcinoma?

Yes, clinical trials may be available, particularly for advanced or recurrent disease. These trials often explore newer targeted therapies or immunotherapies.

Should patients seek a second opinion for fibrolamellar carcinoma?

Given the rarity of the condition, a second opinion from a specialist centre experienced in rare liver cancers can be helpful in confirming diagnosis and treatment planning.

How often are follow-up scans needed after treatment?

Follow-up schedules vary but typically involve regular imaging and blood tests at defined intervals, especially during the first few years after treatment.

Can fibrolamellar carcinoma affect mental or emotional wellbeing?

Yes, coping with a rare cancer can be emotionally challenging. Psychological support, counselling, and patient support services are often beneficial for both patients and families.

Is travel safe after treatment for fibrolamellar carcinoma?

Most patients can travel once medically stable, but long-distance or international travel should be discussed with the treating doctor, particularly during early follow-up periods.

Does fibrolamellar carcinoma require lifelong monitoring?

Long-term monitoring is usually recommended, as ongoing surveillance helps detect recurrence early and supports overall long-term health management.

Reviewed by Dr Ajit Singh Oberoi, Consultant – Surgical Oncology, GI and Thoracic Oncology, on 27 March 2026.